Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Why Rheumatologists Should Ask Patients About Drug Use

Larry Beresford  |  Issue: September 2016  |  September 8, 2016

megaflopp/shutterstock.com

megaflopp/shutterstock.com

SAN FRANCISCO—“We’ve known for a long time that prescription medications and illicit drugs can both mimic and actually induce the autoimmune syndromes treated by rheumatologists,” Jonathan Graf, MD, professor of medicine at the University of California–San Francisco in the Division of Rheumatology at Zuckerberg San Francisco General Hospital (SFGH), said at the California Rheumatology Alliance 2016 Scientific & Medical Meeting in May.

“There are syndromes associated with drug use that look like their non-drug counterparts, but with particular calling-card features,” Dr. Graf explained in a follow-up interview with The Rheumatologist. The worst of these is vasculitis. “It’s important for rheumatologists to have a generalized understanding of the drugs their patients may take, legal or not, that [have an] impact on autoimmune diseases. For many of these syndromes, you have an obvious treatment—get the patient to stop taking the drug and the condition may abate.” Unfortunately, there is little evidence to support medical treatments for some of these drug-related syndromes, he said, although skin grafts, antibiotics and systemic corticosteroids have been tried.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Detective Work

In his presentation, Dr. Graf described some detective work done by the rheumatologists at SFGH on a sequence of eight patients admitted to the hospital in 2009, starting with a 46-year-old woman who presented with cyanosis in her lower extremities. These patients presented a distinct syndrome with a puzzling mix of clinical manifestations including necrotic retiform purpura on the face and ears, skin necrosis, vasculopathy, neutropenia and acute kidney injury, along with characteristic autoantibody profiles and other laboratory findings. “The syndrome we were seeing had features that were not classic vasculitis. We realized there was a common thread, which was cocaine use, but not the classic syndrome of that.”

After a thorough investigation, it turned out they all were using cocaine that had been adulterated with levamisole, an anti-parasitic agent used in veterinary medicine and once a treatment for rheumatoid arthritis until it was discontinued in 1990 due to side effects. An advisory from the federal Substance Abuse and Mental Health Services Administration around the same time reported that 70% of the cocaine tested in July 2009 by the Drug Enforcement Administration was positive for levamisole.1 Since then, levamisole adulteration has been on the rise, although the full extent of the syndrome is not fully appreciated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This relatively new phenomenon is just the tip of the iceberg when it comes to rheumatologic disorders secondary to drug use, Dr. Graf said. “We’ve been called in with patients to rule out vasculitis. I’m now getting called in to see every weird cocaine toxicity in the hospital.” The rheumatologist often sees disease patterns for which the cause is unknown—or else genetically linked. In cases where features associated with drug use are present, it would be good to do a work-up for drug use, including a thorough medication history and, in some cases, urine drug screening. “Ask your patients about their drug use.”

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsPractice Support Tagged with:California Rheumatology Alliance 2016Diagnosisdrug usepatient careRheumatic Diseaserheumatologist

Related Articles

    Fellow’s Forum Case Report: True Vasculitis or Vasculitis Mimic?

    October 1, 2012

    Rheumatologists face the emerging picture of cocaine and levamisole-associated vasculopathy in clinical practice

    Turn Down the Pain Volume

    October 1, 2009

    Fibromyalgia’s evolution from discrete entity to prototypical central pain syndrome

    Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

    Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

    June 15, 2017

    Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…

    ilusmedical / shutterstock.com

    The State of Clinical Research in Vasculitis: 2021

    January 19, 2021

    It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences